Vext Science (TSE:VEXT) has released an update.
Vext Science reports a solid Q1 2024 with $8.4 million in revenue and $1.9 million in adjusted EBITDA, despite a challenging consumer environment. Poised for growth, Vext anticipates benefits from the upcoming adult-use program in Ohio and has secured a $2 million credit facility to support operations and seize market opportunities.
For further insights into TSE:VEXT stock, check out TipRanks’ Stock Analysis page.
